UTAH MEDICAL PRODUCTS INC (UTMD)
Health Care · medical devices · NASDAQ
A developer and manufacturer of specialized medical devices for neonatal, obstetric, and women's health applications with a strong history of high profit margins and recurring dividends.
What UTAH MEDICAL PRODUCTS INC does
Utah Medical Products manufactures and markets specialty medical devices, primarily focused on neonatal, labor and delivery, and women's health care settings. The company also produces components and finished devices on a subcontract basis for other medical device and non-medical companies. Its products are sold directly to clinical facilities or through distribution relationships globally.
Recent developments
Consolidated revenues declined in 2Q 2026 due to the loss of sales to the company's two previously largest customers. Management is working to recover this volume through new biopharma OEM business, though gains have been slower than initially expected.
From UTAH MEDICAL PRODUCTS INC's filing of 2026-08-12.
Themes: women's health, neonatal care, obstetrics, biopharma OEM
Fundamentals
- Price$73.88 as of 2026-10-08 close
- Market cap$235M as of 2026-08-11 (share count; price 2026-10-08)
- 1-year return+16.5% 2025-10-08 close $63.43 → 2026-10-08 close $73.88
- P/E21.86 as of 2026-10-08
- Net margin+29.3% FY2025, SEC XBRL
- Gross margin+57.1% FY2025, SEC XBRL
- ROE+9.5% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-4.4% as of 2026-09-02
- Revenue CAGR (3y)-9.7% SEC XBRL
- Beta0.35 as of 2026-09-02
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.7%; pays a dividend.
How UTMD compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, UTMD's dividend was covered by reported results (earnings payout 35%, free-cash-flow payout 28%). This describes past coverage, not a forecast.
- Earnings payout35% dividends / net income
- Free-cash-flow payout28% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How UTAH MEDICAL PRODUCTS INC looks technically
UTAH MEDICAL PRODUCTS INC (UTMD) is trading 10.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 172 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago. It is 3.9% below its 52-week high (its highest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 10.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +10.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $72.29 | $72.29 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $66.64 | $66.64 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 172 trading days ago — a "golden cross", a bullish long-term signal | 172 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 16.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($73.22 to $76.89) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $76.89 | $76.89 |
|---|---|---|
| From the 52-week high | it is 3.9% below its 52-week high (its highest price of the past year) | -3.9% |
| Above the 52-week low | it is 37.7% above its 52-week low (its lowest price of the past year) | +37.7% |
| Below the 52-week high | it is 3.9% below its highest point of the past year | 3.9% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $133.87 (set on 2021-11-22) | $133.87 |
| Given back of the 52-week move | over the past year its closes ranged ($53.80 to $76.66), and it has given back only a small part of its rise from last year’s low — 12% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $61.80 to $62.53. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 12.2% |
| From the all-time high | it is 44.8% below its all-time high | -44.8% |
| Nearest price level | it is trading 0.6% above a support level at $73.42 — a price it turned at twice since 2026-08-19, most recently on 2026-08-28. Since 2024-10-08 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $20.04 (set on 2008-12-26) | $20.04 |
| Above the all-time low | it is 268.6% above its all-time low | +268.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.17 between its high and its low — about 1.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.17 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $71.08 and $76.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $71.08 – $73.94 – $76.80 |
| Typical daily range (% of price) | its price moves about 1.6% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 1.6% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges above its 200-day average price (10.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.92× |
|---|
Candlestick patterns
1
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.2% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-03 has been "filled" 45 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 45 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.8 percentage points (the stock gained 6.8% while the market gained 1.0%) | +5.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.7 percentage points (the stock gained 8.5% while the market gained 3.8%) | +4.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 0.1 percentage points (the stock gained 17.4% while the market gained 17.5%) | -0.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 1.5 percentage points (the stock gained 16.5% while the market gained 15.0%) | +1.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.3% of the share price. | +3.3% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $68.85 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +7.3% |
|---|
Price levels it has turned at before
UTMD last closed at $73.88 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $73.42 | Support | 0.6% below the last close | turned there twice · 2026-08-19 to 2026-08-28 |
| $75.38 | Resistance | 2.0% above the last close | turned there twice · 2026-06-26 to 2026-08-03 |
| $72.17 | Support | 2.3% below the last close | turned there twice · 2026-04-17 to 2026-07-16 |
| $70.09 | Support | 5.1% below the last close | turned there twice · 2026-06-16 to 2026-08-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Least volatile (2% or less typical daily range) · Stretched far above its 200-day average (6+ daily ranges) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["Loss of revenue from major OEM/distributor customers","Increased regulatory burdens and potential premarketing approval delays","Impact of legislative or government-run healthcare interference on market predictability"]
What changed in the latest 10-Q
AI-assisted comparison of UTMD's 10-Q filed 2026-05-12 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Form 10-K for year ended December 31, 2025 (older filing referenced year ended December 31, 2024)
- Newer filing compares 1Q 2026 to 1Q 2025 results; older filing compared 3Q 2025 and 9M 2025 to prior year periods
- Newer filing includes specific narrative about loss of sales to China distributor and PendoTECH customer in 1Q 2026 with combined $857 in 1Q 2025 sales representing 87% of sales decline
- Newer filing discusses constant currency analysis showing additional $169 lower OUS sales due to weaker USD in 1Q 2026
- Newer filing includes statement: 'Historically, sales to UTMD's largest OUS distributor in China had a significantly lower Gross Profit Margin'
- Newer filing specifies one-time yearly adjustment to standard costs which increased inventory value affecting 1Q 2026 gross profit
- Newer filing details specific expense increases: $127 higher litigation expenses, $147 higher employee health care costs, $65 higher OUS operating expenses in 1Q 2026
- Newer filing mentions 96,864 shares repurchased during four calendar quarters following end of 1Q 2025
- Newer filing states cash equivalent balances were $4.1 million higher at March 31, 2026 than March 31, 2025 after using $9.5 million for repurchases, dividends and equipment
- Newer filing reports Stockholders' Equity of $120.4 million at end of 1Q 2026, improved $1.1 million from three months earlier
- Newer filing includes section on Revenues with discussion of T&C of Sale and pricing agreements with clinical facilities
- Removed:
- Older filing's discussion of 3Q 2025 financial performance affected by foreign trade events and cancellation of non-changeable orders by two OUS distributors
- Older filing's narrative about $976 lost shipments, $581 lost revenues, EUR 360 cancellation fee, and $395 bad debt reserve for China distributor
- Older filing's detailed comparison table of WW Operating Expenses excluding litigation and IIA amortization for 3Q and 9M periods
- Older filing's separate tables showing Litigation Expense and UK IIA Amortization Expense for 3Q and 9M comparison periods
- Older filing's statement about September 30, 2025 Balance Sheet being stronger than end of 2024 with higher current ratio and lower total liabilities
- Older filing's reference to 9M 2025 cash payments of $3,006 in dividends and $7,361 for share repurchases
- Older filing's statement that 3Q 2025 ending share price increased $1.50 (+2.4%) from end of 2024
- Reworded:
- Currency notation changed from 'A$ or AUD' in older filing to 'AUD' in newer filing
- Older filing noted Form 10-K covered year ended December 31, 2024; newer filing covers year ended December 31, 2025
- Older filing discussed 'non-prepayment as a practical matter' affecting distributor orders; newer filing uses past tense regarding distributor and OEM customer losses
- Older filing emphasized 'unusually affected by foreign trade events'; newer filing presents distributor/OEM customer losses as expected and previously reported
- Notes:
- Newer filing text appears truncated at the end of revenues section (incomplete sentence about pricing)
- Older filing also appears truncated at the end (incomplete 'Foreign currency exchange (FX) rate' section)
- Comparison involves different reporting periods (1Q 2026 vs. 3Q/9M 2025), making some items non-comparable
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for UTMD — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding UTMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 461,509
- Reported value $31,854,062
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about UTMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
UTMD had 172,180 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
UTMD had 5.41% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.53 days to cover at the same settlement.
- Reported short interest (shares) 172,180
- Short interest (% of shares outstanding) 5.41%
- Prior settlement (shares) 166,805
- Reported change 3.22%
- Days to cover (reported) 4.53
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CooperSurgical
- Bard Access Systems (BD)
- C.R. Bard (BD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does UTAH MEDICAL PRODUCTS INC (UTMD) do?
Utah Medical Products manufactures and markets specialty medical devices, primarily focused on neonatal, labor and delivery, and women's health care settings. The company also produces components and finished devices on a subcontract basis for other medical device and non-medical companies. Its products are sold directly to clinical facilities or through distribution relationships globally.
What sector is UTAH MEDICAL PRODUCTS INC (UTMD) in?
UTAH MEDICAL PRODUCTS INC (UTMD) is classified in the Health Care sector. Its industry is medical devices. It trades on NASDAQ.
Does UTMD pay a dividend?
Yes — UTAH MEDICAL PRODUCTS INC (UTMD) pays a dividend, with an indicated yield of about 1.68% (market data, as of 2026-09-02). Informational only — not financial advice.
Who are UTAH MEDICAL PRODUCTS INC's (UTMD) competitors?
Notable peers of UTAH MEDICAL PRODUCTS INC (UTMD) include CooperSurgical, Bard Access Systems and C.R. Bard. This peer set is informational only — not financial advice.
Is UTAH MEDICAL PRODUCTS INC (UTMD) overbought or oversold right now?
UTAH MEDICAL PRODUCTS INC (UTMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on UTMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.